Klow

Branded four-component research blend

Research overview

Klow is a branded formulation rather than a single compound. Ironfield declares its composition as TB-500 10 mg, BPC-157 10 mg, GHK-Cu 50 mg and KPV 10 mg. No published study examines this combination, and nothing here should be read as describing the blend: each citation concerns a single component in isolation. Philp and colleagues examined thymosin beta-4 and a synthetic peptide containing its actin-binding domain, the sequence sold as TB-500, in dermal repair models. Seiwerth and colleagues reviewed the stable gastric pentadecapeptide BPC 157 in wound-healing research. Pickart and Margolina reviewed gene-expression data for the copper-binding tripeptide GHK-Cu. Dalmasso and colleagues characterised PepT1-mediated uptake of the tripeptide KPV and measured intestinal inflammatory markers. Combination effects, interactions between components, and the stability of the mixture are not addressed anywhere in the cited record.

What the literature studies

• ▸Each component in isolation; the four-way combination is unstudied
• ▸Actin sequestration and dermal repair models for thymosin beta-4 and its actin-binding fragment
• ▸Wound-healing research on the pentadecapeptide BPC 157
• ▸Gene-expression data for the copper-binding tripeptide GHK-Cu
• ▸PepT1-mediated uptake and intestinal inflammatory markers for the tripeptide KPV

Declared composition

TB-50010 mg

The synthetic fragment containing the actin-binding domain of thymosin beta-4.

BPC-15710 mg

A pentadecapeptide sequence derived from a gastric protein.

GHK-Cu50 mg

A copper-binding tripeptide.

KPV10 mg

A tripeptide corresponding to the C-terminal fragment of alpha-MSH.

From the Ironfield research guide (p23)

Klow is treated here as a brand-specific research formulation. Composition-specific data should be supplied separately through the product label, COA, and technical documentation so researchers can assess mechanism and handling requirements.

Sources

1. 01Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. PubMed 12581423
2. 02Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PubMed 34267654
3. 03Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PubMed 29986520
4. 04Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PubMed 18061177

Current evidence varies by compound. Many products discussed in this guide remain investigational, are not approved for general clinical use, and should only be handled under qualified research protocols.

No dosing, administration, or treatment instructions are provided.